This site is intended for health professionals only

Published on 28 October 2013

Share this story:
Twitter
LinkedIn

Global Lung Cancer Coalition

 

 

The Global Lung Cancer Coalition (GLCC) has announced, at the 15th World Conference on Lung Cancer (WCLC) in Sydney, Australia, a campaign, supported by Boehringer Ingelheim (BI), to increase the knowledge and understanding of real world challenges facing individuals and families battling lung cancer.
‘Lung Cancer: We’re Listening’ will gather much needed feedback from individuals touched by lung cancer – including patients, carers, family members, friends, healthcare professionals and work colleagues.
“By gathering insights and listening to real-life experiences from those directly affected by lung cancer, we can increase our knowledge and understanding of the challenges faced by lung cancer patients,” said Dr Matthew Peters, chair of The Global Lung Cancer Coalition. “This knowledge can be used by the GLCC and shared with appropriate healthcare providers to effect change and improve patient-centric programmes, services and tools. This closely aligns with the GLCC’s commitment to improving outcomes for all lung cancer patients and placing lung cancer squarely on the global health agenda.”
Lung cancer is not only the most common cancer in the world, accounting for 1.6 million new cancer cases each year,(1) but it is also the biggest cancer killer.(2) Lung cancer is not just one disease; there are distinct subtypes and tailored approaches to treatment can improve patient outcomes. However, there is still a lack of understanding of the disease, and its impact on patients and those caring for them. A key driver of ‘Lung Cancer: We’re Listening’ is a global need to better understand the real world challenges of lung cancer patients. By learning more about their specific challenges with many topics, including relating to changes in roles and relationships, stigmatisation, and difficulty communicating with their healthcare team, the campaign will help to improve the support and information available to them.
‘Lung Cancer: We’re Listening’ adopts a unique approach to gathering patient feedback by minimising the text-based feedback format and focusing on presenting the survey visually. A novel online tool, with a simple navigation, asks respondents to click on predefined graphics, symbols and elements within a web-based visual world to give their feedback on issues that are relevant to them. The visual elements represent challenges and issues of importance in the lives of lung cancer patients and their caregivers and families. The graphics and symbols they select will reveal their most pressing issues and concerns, mirroring over time the lung cancer patient’s real world agenda and experiences.
This approach is the first of its kind designed to ‘listen in’ on the real world of lung cancer patients, and bridge the gap between healthcare providers and their patients’ situations. Results will be shared with the lung cancer community and the insights shared with those involved in providing patient services to aid the development of new programmes, services and educational materials that better meet patients’ needs.
“We need to understand how patients feel, in order to better help them,” said Prof Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. “With patients at the centre of our commitment to oncology, together with the GLCC we can use ‘Lung Cancer: We’re Listening’ to inform programmes on a global scale and to develop more effective approaches to support the lung cancer community by improving patients’ lives beyond treatment.”
The ‘Lung Cancer: We’re Listening’ website will launch in mid-November to coincide with Lung Cancer Awareness Month.
References
  1. Ferlay J, ShinHR, Bray F, et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
  2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin2005;55:74-108.


Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn